Table I.
Characteristic | Total | Poor prognosis | % | Good prognosis | % | P-value |
---|---|---|---|---|---|---|
All | 195 | 65 | 130 | |||
Age at diagnosis, years | ||||||
<35 | 5 | 2 | 3.1 | 3 | 2.3 | |
35 to <49 | 94 | 31 | 47.7 | 63 | 48.5 | |
>50 | 96 | 32 | 33.3 | 64 | 49.2 | >0.05 |
Mean ± SD | 54.0±10.2 | 54.1±10.1 | >0.05 | |||
Menopausal status | ||||||
Premenopausal | 92 | 30 | 46.2 | 62 | 48.0 | |
Postmenopausal | 103 | 35 | 53.8 | 68 | 52.0 | >0.05 |
Tumor size | ||||||
T1a+T1b | 6 | 2 | 3.1 | 4 | 3.1 | |
T1c | 40 | 14 | 21.5 | 26 | 20.0 | |
T2 | 137 | 45 | 69.2 | 92 | 70.8 | |
T3 | 12 | 4 | 6.2 | 8 | 6.1 | >0.05 |
Family history | ||||||
Yes | 29 | 9 | 13.8 | 20 | 15.4 | |
No | 166 | 56 | 86.2 | 110 | 84.6 | >0.05 |
Peritumoural vascular invasion | ||||||
Absent | 176 | 54 | 83.1 | 123 | 94.6 | |
Present | 19 | 11 | 16.9 | 7 | 5.4 | 0.009 |
Tumor grade | ||||||
Low | 26 | 5 | 7.7 | 21 | 16.2 | |
Intermediate | 128 | 40 | 61.5 | 88 | 67.7 | |
High | 41 | 20 | 30.8 | 21 | 16.2 | 0.031 |
Molecular subtype | ||||||
‘Luminal A-like’ | 59 | 11 | 16.9 | 48 | 36.9 | |
‘Luminal B-like (HER2 negative)’ | 41 | 13 | 20.0 | 28 | 21.5 | |
‘Luminal B-like (HER2 positive)’ | 21 | 8 | 12.3 | 13 | 10.0 | |
‘HER2 positive’ | 23 | 12 | 18.5 | 11 | 8.5 | |
‘Triple negative’ | 51 | 21 | 32.3 | 30 | 23.1 | 0.026 |
Chemotherapy | ||||||
Yes | 152 | 52 | 80.0 | 100 | 76.9 | |
No | 43 | 13 | 20.0 | 30 | 23.1 | >0.05 |
Radiotherapy | ||||||
Yes | 48 | 15 | 23.1 | 33 | 25.4 | |
No | 147 | 50 | 76.9 | 97 | 74.6 | >0.05 |
Endocrine therapy | ||||||
No. of ER positive subtype | 121 | 32 | 49.2 | 89 | 68.5 | |
Yes | 108 | 28 | 43.1 | 80 | 61.5 | |
No | 13 | 4 | 6.1 | 9 | 7.0 | >0.05 |
Statistical tests for categorical variables were performed using the χ2 test; mean age was tested using the Mann-Whitney test. ANN, axillary lymph node-negative; HER2, human epidermal growth factor receptor 2; ER, estrogen-receptor.